Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bafna PharmaceuticalsNSE:BAFNAPH +0.16%60 3-Year EBITDA Growth Rate is 3.30% as of Mar. 2026, which is 71% below its 10-year median of 11.20. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 60/100 and a GF Value™ of ₹91.58 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 809 Drug Manufacturers companies, Bafna Pharmaceuticals ranks worse than 61.43% on this metric.
During the past 12 months, Bafna Pharmaceuticals's average EBITDA Per Share Growth Rate was 75.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 3.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 10.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bafna Pharmaceuticals was 138.10% per year. The lowest was -65.10% per year. And the median was 11.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Bafna Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
NSE:BAFNAPH vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 3.30% mean?
Bafna Pharmaceuticals (NSE:BAFNAPH) has a 3-Year EBITDA Growth Rate of 3.30% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bafna Pharmaceuticals and its competitors. This is 71% below median its historical median of 11.20. According to the industry distribution chart, Bafna Pharmaceuticals ranks #497 out of 809 companies in the Drug Manufacturers industry, placing it in the top 61.4%.
Is Bafna Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Bafna Pharmaceuticals' current 3-Year EBITDA Growth Rate of 3.30% is 71% below median its 10-year median of 11.20. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Bafna Pharmaceuticals' value of 3.30% is 62.9% below this industry median. Based on the distribution chart, Bafna Pharmaceuticals ranks #497 out of 809 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bafna Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #497 out of 809 companies for 3-Year EBITDA Growth Rate. This places Bafna Pharmaceuticals in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Bafna Pharmaceuticals' value of 3.30% is 62.9% below this benchmark. While the company's 10-year median is 11.20 vs. the industry median of 8.90, Bafna Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bafna Pharmaceuticals's current 3-Year EBITDA Growth Rate of 3.30% is 62.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current 3-Year EBITDA Growth Rate is 3.30%, which is 71% below median its own 10-year median of 11.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹91.58, compared to a current price of ₹285.00 — trading 211.2% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 3.30%, which is 71% below median its 10-year median of 11.20 and 62.9% below the Drug Manufacturers industry median of 8.90. Bafna Pharmaceuticals' overall GF Score™ is 60/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current 3-Year EBITDA Growth Rate is 3.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹285.00 is trading 211.2% above its estimated GF Value™ of ₹91.58.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
3-Year EBITDA Growth Rate: 3.30% (71% below median its 10-year median of 11.20)
GF Value™: ₹91.58 vs. price of ₹285.00 (211.2% above fair value)
Industry Position: 62.9% below the Drug Manufacturers median (#497 of 809)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
60GF Score
Get the complete analysis for NSE:BAFNAPH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
